MJN-neuro has opened a €1-million crowdequity round through the Capital Cell platform to finance the marketing plan for the new mjn-SERAS device, the first wearable device that is able to predict the likelihood of suffering an epileptic seizure.

MJN-neuro is one of the 10 companies selected to participate in the BIOMED ScaleUP corporate growth programme run by CataloniaBio & HealthTech.

MJN-neuro has received several international recognitions since its creation in 2014, including the Epilepsy Foundation in the United States, which considers it to be one of the most promising startups offering products to improve the quality of life of people sufferingfrom epilepsy.

There are 125 million people around the world who live with epilepsy.

Invest in MJN-Neuro

You may also be interested in:

• MJN obtains the EC certification for its epilepsy aid solution
• MJN and its device to predict epileptic seizures win prize at IoT Innovation World Cup